Comparison Study of Transversus Abdominal Plane, Paravertebral and Epidural Blocks in Laparoscopic Colectomy
NCT ID: NCT02164929
Last Updated: 2017-09-25
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
17 participants
INTERVENTIONAL
2013-12-31
2015-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Paravertebral block
Bilateral PVB will be placed between T7-T10 interspaces preoperatively. Patients will be in a sitting position which allows easy identification of landmarks, and the patients are often more comfortable. Ultrasound will be used to identify the paravertebral space. At the appropriate dermatome under aseptic precautions, the needle (22-gauge, 8-10-cm short beveled spinal needle) will inserted 2.5-3 cm lateral to the most cephalad aspect of the spinous process and advanced perpendicular to the skin in all planes to contact the transverse process 3 of the vertebra below at a variable depth (2-4 cm). A 10 mL ropivacaine 0.25% will be injected at both T7 and T9 levels on each side (40 mL in total).
Paravertebral block
Acetaminophen 1g IV
Dexamethasone 4mg
Midazolam up to 2mg
Propofol 1-2.5 mg/kg
Sevoflurane to keep a bispectral index of between 40-60
Local infiltration with 10 mL of plain ropivacaine 0.25%
TAP block
Bilateral posterior and subcostal TAP blocks guided by ultrasound will be performed in the preoperative holding area. A total of 80 mL ropivacaine 0.25% (4 injections, 20 mL per injection) will be injected evenly upon identification of the appropriate planes. In the event the placement of block is uncomfortable for the patients, it will be performed after induction of anesthesia. This approach is currently practiced in the OR. Extent and degree of anesthetic blockage will be measured using a 5-point sensation scale following the procedure at 4 areas on the anterior abdominal wall (above and below the umbilicus bilaterally).
TAP block
Acetaminophen 1g IV
Dexamethasone 4mg
Midazolam up to 2mg
Propofol 1-2.5 mg/kg
Sevoflurane to keep a bispectral index of between 40-60
Local infiltration with 10 mL of plain ropivacaine 0.25%
Epidural
An epidural catheter will be inserted between T8-10 in the preoperative holding area, and a test dose of 1.5% lidocaine with 1:200,000 epinephrine will be given. Extent and degree of anesthetic blockage will be measured using a 5-point sensation following the procedure and postoperatively at 4 areas on the anterior abdominal wall (above and below the umbilicus bilaterally).
A bolus does of epidural hydromorphone (400-800 mcg) will be given preoperatively. An infusion of bupivacaine 0.25% at 4-6 ml/hour will be commenced before incision, and if tolerated, continued throughout surgery. Adjustments that may be required secondary to specific patient hemodynamic status will be left to the discretion of the individual anesthesiologist and guided by the specific patient requirements.
Epidural
Acetaminophen 1g IV
Dexamethasone 4mg
Midazolam up to 2mg
Propofol 1-2.5 mg/kg
Sevoflurane to keep a bispectral index of between 40-60
Local infiltration with 10 mL of plain ropivacaine 0.25%
Lidocaine
1.5% lidocaine
Epinephrine
1:200,000 epinephrine
Hydromorphone
400-800 mcg Hydromorphone will be given preoperatively
No block (PCA alone)
Premedication with midazolam up to 2 mg. General anesthesia is induced with propofol 1-2.5 mg/kg. Dexamethasone 4 mg IV will be administered after induction of anesthesia. Anesthesia will be maintained with sevoflurane to keep a bispectral index of between 40-60. Neuromuscular blocking drug and reversal agent of choice may be used. Local infiltration with 10 mL of plain ropivacaine 0.25% will be administered at the surgical incision site at the end of surgery. Acetaminophen 1g IV will be administered following induction of anesthesia will be administered at the end of the procedure
Acetaminophen 1g IV
Dexamethasone 4mg
Midazolam up to 2mg
Propofol 1-2.5 mg/kg
Sevoflurane to keep a bispectral index of between 40-60
Local infiltration with 10 mL of plain ropivacaine 0.25%
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
TAP block
Epidural
Paravertebral block
Acetaminophen 1g IV
Dexamethasone 4mg
Midazolam up to 2mg
Propofol 1-2.5 mg/kg
Sevoflurane to keep a bispectral index of between 40-60
Local infiltration with 10 mL of plain ropivacaine 0.25%
Lidocaine
1.5% lidocaine
Epinephrine
1:200,000 epinephrine
Hydromorphone
400-800 mcg Hydromorphone will be given preoperatively
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients scheduled to undergo laparoscopic colectomy without stoma under general anesthesia
* American Society of Anesthesiology (ASA) Physical Class 1-3.
Exclusion Criteria
* Perineal resection
* Stoma formation
* Patients with a contraindication to TEA or regional anesthesia.
* Pregnancy, nursing, or planning to become pregnant during the study or within one month.
* Long-acting opioid medication within 3 days.
* Any opioid medication within 24 hours.
* Body weight less than 50 kilograms (\~110 pounds)
* Uncontrolled anxiety, schizophrenia, or other psychiatric disorder
* Current or historical evidence of any clinically significant disease or condition that, in the opinion of the Investigator, may increase the risk of surgery or complicate the subject's postoperative course.
* Administration of an investigational drug within 30 days or 5 elimination half-lives of such investigational drug, whichever is longer, prior to study drug administration, or planned administration of another investigational product or procedure during the subject's participation in this study.
* Suspected, or known addiction to or abuse of illicit drug(s), prescription medicine(s), or alcohol within the past 2 years.
* Significant medical conditions or laboratory results that, in the opinion of the Investigator, indicate an increased vulnerability to study drugs and procedures, and expose the subject to an unreasonable risk as a result of participating in this clinical trial, such as: debilitating diseases, acute illnesses, hypotension, partial or complete conduction block, impaired cardiac function, untreated hypertension, advanced arteriosclerotic heart disease, cerebral vascular insufficiency, pre-existing abnormal neurological or neuromuscular disease (e.g., epilepsy, myasthenia gravis), advanced liver disease, severe renal impairment, advanced diabetes, comorbid conditions associated with an immunocompromised status, such as blood dyscrasias, HIV/AIDS, or recent chemotherapy.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Duke University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Duke University Medical Center
Durham, North Carolina, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Pro00047810
Identifier Type: -
Identifier Source: org_study_id